Up to 450% mark-up on knee implants, govt may cap prices

  • News
  • August 15, 2017

New Delhi :  Just like stents, the National Pharmaceutical Pricing Authority (NPPA) has revealed the unrealistic trade margins enjoyed by sellers of orthopaedic (knee) implants medical devices . According to the analysis done by the NPPA, the average trade margins on some of the devices used in knee implants are as high as 449 per cent. The total trade margin on five implant components used in the knee range between 211 per cent and 449 per cent. As a result, an insert, which has a landed price of ₹14,071 finally costs the patient ₹1.03 lakh – 449 per cent higher, a price sheet from the NPPA showed. A similar exercise conducted by the Authority before bringing the prices of coronary stents under strict price control, which had shown that between the pharmaceutical company and the patient, trade margins of as much as 1026 per cent were added to the life-saving devices. As a result of which, a stent with a landed cost of about₹40,820 could finally burn a hole worth ₹1.98 lakh in the patient’s pocket. The Authority had finally capped the prices of stents in February, decreasing the maximum retail price by 80 per cent for some devices. It is estimated that over two lakh replacement surgeries are conducted in India and the market is growing at an estimated 26-30 per cent annually.

  • Related Posts

    13 Years after Oxytocin Order, HC Seeks Compilance Status

    GWALIOR: The Gwalior Bench of the Madhya Pradesh High Court has directed the state government to submit a comprehensive compliance status report. This order addresses the implementation of the court’s…

    Centre Pushes Haryana to Fast-Track AIIMS Rewari

    New Delhi | August 18, 2025 — The Union government has urged Haryana to speed up work on AIIMS Rewari (Majra) and resolve on-ground hurdles so the institute can open…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    PGIMS recalls drug amid probe into deaths

    PGIMS recalls drug amid probe into deaths

    NPPA list brings little relief: No price cut for 25% cancer drugs

    NPPA list brings little relief: No price cut for 25% cancer drugs

    Centre Mandates Minimum One-Year Shelf Life For Imported Drugs

    Centre Mandates Minimum One-Year Shelf Life For Imported Drugs

    For Aakash Healthcare, Community People are Apples of its Eyes

    For Aakash Healthcare, Community People are Apples of its Eyes

    Not mandatory to recall stocks released to the market prior to implementation of TMR: NPPA

    Not mandatory to recall stocks released to the market prior to implementation of TMR: NPPA

    Yashoda Medicity: Baby takes a Giant Step in just One Year

    Yashoda Medicity: Baby takes a Giant Step in just One Year